The WACC of Nirvana Life Sciences Inc (NIRV.CN) is 2.9%.
| Range | Selected | |
| Cost of equity | 1.20% - 3.40% | 2.30% |
| Tax rate | 25.90% - 26.50% | 26.20% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 3.5% - 2.2% | 2.9% |
| Category | Low | High |
| Long-term bond rate | 3.2% | 3.7% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | -3.28 | -3.28 |
| Additional risk adjustments | 17.0% | 17.5% |
| Cost of equity | 1.20% | 3.40% |
| Tax rate | 25.90% | 26.50% |
| Debt/Equity ratio | 0.7 | 0.7 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 3.5% | 2.2% |
| Selected WACC | 2.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for NIRV.CN:
cost_of_equity (2.30%) = risk_free_rate (3.45%) + equity_risk_premium (5.60%) * adjusted_beta (-3.28) + risk_adjustments (17.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.